Latest Conference Articles

February 20th 2015, 8:12am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Michael Mauro, MD, hematologist and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center, discusses treatment discontinuation for patients with chronic myeloid leukemia.

February 20th 2015, 7:11am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Oncologists, hematologists, and other experts on hematologic malignancies will convene for the 19th Annual International Congress on Hematologic Malignancies, from February 20-21 in Miami, Florida, to provide insight into recent developments in the treatment of the diseases.

February 11th 2015, 2:29pm

PER® New York Lung Cancer Symposium

Abraham Chachoua, MD, associate director of cancer services at NYU Langone Medical Center, talks about targeted treatment for mutations in non-small cell lung cancer and adenocarcinoma.

January 21st 2015, 10:21am

Gastrointestinal Cancers Symposium (ASCO GI)

Treatment with a multitargeted tyrosine kinase inhibitor led to a small but statistically significant improvement in progression-free survival (PFS) in patients with advanced, previously treated metastatic colorectal cancer.

January 20th 2015, 11:14am

ASH Annual Meeting and Exposition

Results from a pair of phase II studies indicate that adding the immunomodulatory agent pomalidomide (Pomalyst) to multiple myeloma regimens improved outcomes for patients who have stopped responding to earlier treatments.

January 20th 2015, 8:09am

ASH Annual Meeting and Exposition

Clinicians who treat patients with multiple myeloma have witnessed a sea change in the past 15 years. Yet another revolution appears right around the corner.

January 18th 2015, 10:20am

Gastrointestinal Cancers Symposium (ASCO GI)

Almost half of patients with borderline resectable or locally advanced pancreatic cancer had objective responses to treatment with an investigational chemokine receptor antagonist.

January 17th 2015, 1:50pm

Gastrointestinal Cancers Symposium (ASCO GI)

Lanreotide improved progression-free survival and resulted in more disease control compared with an observation strategy among patients with pancreatic neuroendocrine tumors.

January 17th 2015, 12:36pm

Gastrointestinal Cancers Symposium (ASCO GI)

An analysis of patients with advanced hepatocellular carcinoma and elevated α-fetoprotein who received second-line ramucirumab showed a significant improvement in overall survival.

January 17th 2015, 12:02pm

Gastrointestinal Cancers Symposium (ASCO GI)

Expanded analysis of the NAPOLI-1 trial's per-protocol population continues to support the benefit of adding the nanoliposomal encapsulation of irinotecan MM-398 to 5-fluorouracil plus leucovorin for the treatment of patients with metastatic pancreatic cancer who were previously treated with gemcitabine.

January 17th 2015, 10:54am

Gastrointestinal Cancers Symposium (ASCO GI)

Two polymorphisms of a vasodilatory enzyme had significant associations with improved survival in liver cancer treated with an inhibitor of vascular endothelial growth factor receptor (VEGFR), data from a retrospective study reported at the 2015 Gastrointestinal Cancers Symposium showed.

January 17th 2015, 10:29am

Gastrointestinal Cancers Symposium (ASCO GI)

Andrea Wang-Gillam, MD, PhD, assistant professor, Department of Medicine, Oncology Division, Washington University School of Medicine in St. Louis, discusses a combination treatment of PF-04136309 with FOLFIRINOX for borderline resectable and locally advanced pancreatic adenocarcinoma (PC).

January 16th 2015, 4:38pm

Gastrointestinal Cancers Symposium (ASCO GI)

Manish A. Shah, MD, talks about a recent phase II study of mFOLFOX paired with the MET inhibitor onartuzumab for the treatment of metastatic, HER2-negative gastroesophageal adenocarcinoma (GEC).

January 16th 2015, 4:00pm

Gastrointestinal Cancers Symposium (ASCO GI)

Changing the administration schedule for gemcitabine plus nab-paclitaxel from weekly to every other week significantly reduced side effects without impacting efficacy as a frontline treatment for patients with metastatic pancreatic cancer.

January 16th 2015, 3:27pm

Gastrointestinal Cancers Symposium (ASCO GI)

Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses the impact of the approval of lanreotide.

January 16th 2015, 3:21pm

Gastrointestinal Cancers Symposium (ASCO GI)

The CLARINET study led to the approval of lanreotide (Somatuline Depot) for the treatment of patients with advanced unresectable, metastatic gastrointestinal and pancreatic neuroendocrine tumors (GEP-NETs.)

January 16th 2015, 9:27am

Gastrointestinal Cancers Symposium (ASCO GI)

Patients with advanced, MET-amplified gastroesophageal cancer had a high likelihood of response to an investigational MET inhibitor, results from a preliminary, dose-escalation trial suggested.

January 15th 2015, 4:53pm

Gastrointestinal Cancers Symposium (ASCO GI)

Among patients with metastatic gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab, the agent showed promising antitumor activity and a manageable toxicity profile.

January 15th 2015, 4:48pm

Gastrointestinal Cancers Symposium (ASCO GI)

Chiara Cremolini, MD, discusses findings from the phase III TRIBE trial that combined FOLFOXIRI with bevacizumab as a frontline treatment for patients with metastatic colorectal cancer.

January 15th 2015, 4:31pm

Gastrointestinal Cancers Symposium (ASCO GI)

Eric Van Cutsem, MD, PhD of University Hospitals Gasthuisberg/Leuven, Leuven, Belgium, discusses the use of trastuzumab for the treatment of advanced HER2-positive gastric cancer.